RxDoctor Payments Data

Michelle Plaster, MD

Family Medicine · Monroe, GANPI 1073762720

Payments from drug & device makers

$8,718in general payments, 2019–2025

Across 571 payments — averaging $15.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$1K
  • Amgen$719
  • AstraZeneca$568
  • Lilly USA, LLC$546
  • Pfizer$393
  • plus $4K from 49 others

What the payments were for

  • Food & beverage$8,62999%
  • Education$891%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk120$1,376
AbbVie(2 entities)87$1,037
Amgen(2 entities)43$719
AstraZeneca39$568
Lilly USA, LLC34$546
Pfizer25$393
Abbott19$361
GSK19$310
Amarin Pharma, Inc.16$284
Astellas Pharma US Inc10$226
Merck16$216
Takeda Pharmaceuticals U.S.A., Inc.12$190
Corcept Therapeutics9$184
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC11$163
Radius Health, Inc.6$156
Avanir Pharmaceuticals, Inc.8$140
Teva Pharmaceuticals USA, Inc.5$135
Dexcom, Inc.5$107
Johnson & Johnson7$95
Biohaven Pharmaceuticals, Inc.5$85
Exact Sciences5$85
Boehringer Ingelheim5$82
Corium, LLC3$80
Lucid Diagnostics Inc.1$73
Novartis4$71
Paratek Pharmaceuticals, Inc.4$70
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)1$69
Endo Pharmaceuticals Inc.4$66
Sanofi-aventis U.S. LLC4$63
Otsuka America Pharmaceutical, Inc.3$58
Nestle Healthcare Nutrition Inc.3$57
ARS Pharmaceuticals Operations, Inc.2$55
Idorsia Pharmaceuticals US Inc4$52
Upsher-smith Laboratories LLC3$51
Biohaven Pharmaceutical Holding Company Ltd.3$49
Supernus Pharmaceuticals, Inc.3$48
Xeris Pharmaceuticals, Inc.2$44
Axsome Therapeutics, Inc.2$42
Scilex Pharmaceuticals Inc.2$42
Currax Pharmaceuticals LLC2$30
Sanofi Pasteur Inc.1$21
Sunovion Pharmaceuticals Inc.1$21
Azurity Pharmaceuticals, Inc.1$18
Optinose US, Inc.1$18
Strongbridge US Inc.1$18
Neos Therapeutics, LP1$17
Acella Pharmaceuticals, LLC1$16
Sumitomo Pharma America, Inc.1$16
Eisai Inc.1$16
Mylan Pharmaceuticals Inc.1$15
UCB, Inc.1$14
Ironshore Pharmaceuticals Inc.1$14
Nalpropion Pharmaceuticals LLC1$14
Lupin Inc.1$13
Linus Health, Inc.1$10

How this compares

$8,718 in reported general payments places this provider in the 90th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$384,681
Medicare patients
604
Services billed
7,690

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide340$402,540
MounjaroTirzepatide176$194,787
EliquisApixaban142$160,827
JardianceEmpagliflozin119$135,356
FarxigaDapagliflozin Propanediol117$107,971
ProliaDenosumab57$95,730
RybelsusSemaglutide63$85,798
MyrbetriqMirabegron115$85,674
JanuviaSitagliptin Phosphate80$79,558
LinzessLinaclotide92$74,309
Trelegy ElliptaFluticasone/Umeclidin/Vilanter82$68,261
TrulicityDulaglutide49$67,799
XareltoRivaroxaban48$54,760
Janumet XrSitagliptin Phos/Metformin Hcl26$35,667
Breztri AerosphereBudesonide/Glycopyr/Formoterol42$34,634

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,376$488,339403 claims
Lilly USA, LLCMounjaro, Trulicity$546$262,586225 claims
PfizerEliquis, Abrysvo$393$175,465189 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix, Arexvy, Anoro Ellipta$310$158,974354 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$568$155,605190 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$82$155,118143 claims
MerckJanuvia, Janumet Xr$216$115,226106 claims
AbbVieLinzess, Vraylar, Synthroid$1,037$114,240206 claims
AmgenProlia$719$95,73057 claims
Astellas Pharma US IncMyrbetriq$226$85,674115 claims
Johnson & JohnsonXarelto$95$54,76048 claims
NovartisEntresto$71$17,92421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Monroe

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →